Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Queensland Health
Cantor Fitzgerald
Cerilliant
Medtronic
Julphar
Chinese Patent Office
Farmers Insurance
Colorcon

Generated: June 21, 2018

DrugPatentWatch Database Preview

FONDAPARINUX SODIUM Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Drug patent expirations by year for FONDAPARINUX SODIUM
Pharmacology for FONDAPARINUX SODIUM
Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Synonyms for FONDAPARINUX SODIUM
104993-28-4
114870-03-0
119329-39-4
129051-67-8
147827-38-1
214767-51-8
350014-67-4
389064-08-8
393796-46-8
393796-99-1
412015-07-7
816468-88-9
AC1LCS4W
AC1NR037
AKOS005146286
alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyr
alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyra
Arixtra
Arixtra (TN)
C31H43N3O49S8.10Na
C31H53N3O49S8
CHEBI:31632
CHEBI:61033
CHEMBL1200644
CHEMBL1201202
D01844
D0NE9T
DB00569
decasodium methyl 2,6-di-O-sulfonato-alpha-D-glucopyranosyl-(1->4)-beta-D-glucopyranosyluronate-(1->4)-2,3,6-tri-O-sulfonato-alpha-D-glucopyranosyl-(1->4)-2-O-sulfonato-alpha-L-idopyranosyluronate-(1->4)-2,6-di-O-sulfonato-al
decasodium salt
DTXSID10146903
Epitope ID:150913
fondaparin
Fondaparin sodium
Fondaparinux
Fondaparinux sodium (JAN/USAN/INN)
Fondaparinux sodium [USAN:INN:BAN]
GSK-576428
GTPL6819
HSDB 7845
I06-1946
IC 85158
J177FOW5JL
Methly O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-
methyl 2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1->4)-beta-D-glucopyranuronosyl-(1->4)-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1->4)-2-O-sulfo-alpha-L-idopyranuronosyl-(1->4)-2-deoxy-6-O-
Methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-beta-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-alpha-L-idopyranuronosyl-(1-4)-2-deoxy-
MolPort-006-167-583
Natural heparin pentasaccharide
NTO
Org-31540
Quixidar
SC-28606
SCHEMBL17655218
SR 90107
SR 90107A
SR-90107
SR-90107A
TRISULFOAMINO HEPARIN PENTASACCHARIDE
UNII-J177FOW5JL
UNII-X0Q6N9USOZ
X0Q6N9USOZ
Xantidar
XEKSTYNIJLDDAZ-JASSWCPGSA-F
Y1945

US Patents and Regulatory Information for FONDAPARINUX SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 206918-001 Dec 26, 2017 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Dr Reddys Labs Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 091316-003 Jul 11, 2011 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aurobindo Pharma Ltd FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 206918-004 Dec 26, 2017 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Jiangsu Hengrui Med FONDAPARINUX SODIUM fondaparinux sodium INJECTABLE;SUBCUTANEOUS 206812-004 May 15, 2018 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Cerilliant
Federal Trade Commission
Queensland Health
Argus Health
Cipla
Healthtrust
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.